Prognose

Das durchschnittliche Kursziel der Analysten beträgt +17,62€(+119,43%). Der Median liegt bei +17,62€(+119,43%).

Kaufen	12
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	15 / 18
Levermann-Strategie	-3 / 13

News

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will be presented – DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 posters at SLEEP 2025, the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. “Post-hoc analysis of the pivotal Phase 3 REST-ON clinical trial, restricted to those study participants with the most severe sleepiness at baseline as measured both objectively and subjectively, showed LUMRYZ participants with a median Epworth Sleepiness Scale (ESS) score at Week 13 that was improved to the range at or below that considered normal.» Mehr auf globenewswire.com
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.» Mehr auf zacks.com
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Avadel Pharmaceuticals ADR einen Umsatz von 48,54 Mio€ und ein Nettoeinkommen von −4,55 Mio€

(EUR)	März 2025	YOY
Umsatz	+48,54 Mio	92,75%
Bruttoeinkommen	+43,38 Mio	82,50%
Nettoeinkommen	−4,55 Mio	82,05%
EBITDA	−2,77 Mio	87,59%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+776,63 Mio€
Anzahl Aktien	96,74 Mio
52 Wochen-Hoch/Tief	+15,25€ - +5,62€
Dividenden	Nein
Beta	1,4
KGV (PE Ratio)	−33,32
KGWV (PEG Ratio)	−0,69
KBV (PB Ratio)	+11,88
KUV (PS Ratio)	+4,53

Unternehmensprofil

Avadel Pharmaceuticals plc ist als biopharmazeutisches Unternehmen in den Vereinigten Staaten tätig. Sein führender Produktkandidat ist FT218, eine Formulierung von Natriumoxybat, die sich in einer klinischen Phase-3-Studie zur Behandlung von exzessiver Tagesschläfrigkeit und Kataplexie bei Erwachsenen mit Narkolepsie befindet. Das Unternehmen war früher unter dem Namen Flamel Technologies SA bekannt und änderte im Januar 2017 seinen Namen in Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Dublin, Irland.